HOME ABOUT CONTACT AVAILABLE ISSUES SUBSCRIBE MEDIA & ADS CONFERENCE CALENDAR
LATEST UPDATES » Vol 21, No 08, August 2017 – Eye – the Window to your Soul       » Palm-Sized PCR Device for Rapid Real-Time Detection of Viruses       » Scientists Uncover New Mechanism for Diabetic Neuropathy       » China Enlists AI to Diagnose Breast Cancer       » Philips and Singapore Institute of Advanced Medicine Holdings Sign Agreement to Open First-of-its-kind Oncology Center in Singapore       » Guardian Partners with MyDoc to Address Singapore's Population Health Needs through Integrating Technology and Self-Care       » Database Boosts Shanghai's Technology Aim      
EYE ON CHINA
Zhifei Biological's vaccine approved for clinical test
Chongqing Zhifei Biological Product Co., Ltd. got the approval documents for clinical test of its Mycobacterium Vaccae for Injection (Vaccae) from the SFDA (State Food and Drug Administration).

According to the approval documents, the product could be used as a biological product in Phase III clinical test for the prevention of tuberculosis.

As a product independently-developed and sold by Zhifei Biological, Vaccae could be used as adjuvant drug for the chemotherapy of tuberculosis. The product generated income of CNY 36.64 million, CNY 46.01 million and CNY 41.36 million in 2010, 2011 and the first three quarters of 2012, respectively, with an average gross profit margin of about 89.24%.

According to the 2012 global tuberculosis report issued by the WHO (World Health Organization), a total of 13 vaccines for the prevention of tuberculosis in the world have entered clinical research stage and only India's M.indicus pranii (MIP),which is still being developed, has entered Phase III clinical test stage. According to Zhifei Biological, the approval of the Vaccae to be used in Phase III clinical test means China has caught up with other countries in the study in this field.

Click here for the complete issue.

NEWS CRUNCH  
news Vitafoods Asia 2017: Industry players optimistic of future
news Nestlé Introduces their Singapore R&D Centre
news Vitafoods Asia Elevates 2017 Learning Programme
PR NEWSWIRE  
Asia Pacific Biotech News
EDITORS' CHOICE  

Lady Ganga: Nilza'S Story
COLUMNS  
Subscribe to APBN E-Newsletter
Find us under 'Others' option to receive APBN e-newsletters thrice a month!

APBN Editorial Calendar 2017
January:
Healthcare Focus: LUNGS
February:
War on CANCER
March:
Get to Know TCM
April:
Diabetes: The Big Picture
May:
The Piece of Your Mind - Brain Health/Science
June:
Advocacies in Support of Rare Disease Patients
July:
Food Science & Technology
August:
Eye – the Window to your Soul
September:
Emerging Infectious Diseases
October:
No. 1 Killer — Heart Diseases
November:
Diseases threatening our Children
December:
Skin Diseases/Allergic Reactions
Editorial calendar is subjected to changes.
MAGAZINE TAGS
About Us
Events
Available issues
Editorial Board
Letters to Editor
Instructions to Authors
Advertise with Us
CONTACT
World Scientific Publishing Co. Pte. Ltd.
5 Toh Tuck Link, Singapore 596224
Tel: 65-6466-5775
Fax: 65-6467-7667
» For Editorial Enquiries:
   biotech_edit@wspc.com or Ms Carmen
» For Subscriptions, Advertisements &
   Media Partnerships Enquiries:
   biotech_ad@wspc.com
Copyright© 2017 World Scientific Publishing Co Pte Ltd  •  Privacy Policy